Best Biotech Stocks For 2021

This article is reprinted by permission from NextAvenue.org. It is part of a partnership withChasing the Dream.

Job openings have been at record highs and the unemployment rate has edged down to all-time lows. But its a very different story for older unemployed Americans, especially ones out of work for over six months the long-term unemployed.

A stunning 33% of job seekers ages 55 and older are long-term unemployed, according to the AARP Public Policy Institute. The average length of unemployment for the roughly 1.2 million people 55+ who are out of work: seven to nine months. Its emotionally devastating for them, said Carl Van Horn, director of Rutgers UniversitysJohn J. Heldrich Center for Workforce Development, at a Town Hall his center and the nonprofitWorkingNationheld earlier this year in New Brunswick, N.J.

Best Biotech Stocks For 2021: BRT Realty Trust(BRT)

We are a real estate investment trust, also known as a REIT. During the past three years, we engaged in three principal business activities: the ownership, operation and development of multi-family properties; the ownership, operation and development of commercial, mixed use and other real estate assets; and real estate lending. Beginning in March 2012, we commenced and expanded our multi-family activities, and in 2014, we de-emphasized our real estate lending activities. As of November 1, 2014, we are no longer engaged in real estate lending and the financial information, including our consolidated financial statements included herein, have been reclassified to present our real estate lending activities as discontinued operations. See Note 1 to our consolidated financial statements. Our multi-family property activities involve the ownership, operation and development, primarily through joint ventures in which we typically have an 80% equity interest, of such properties.   Advisors’ Opinion:

  • [By Logan Wallace]

    BRT Apartments Corp (NYSE:BRT) – Equities researchers at B. Riley reduced their FY2018 EPS estimates for BRT Apartments in a research report issued on Tuesday, August 21st. B. Riley analyst C. Kucera now forecasts that the financial services provider will post earnings of $0.94 per share for the year, down from their prior forecast of $1.13. B. Riley also issued estimates for BRT Apartments’ Q4 2018 earnings at $0.18 EPS, Q1 2019 earnings at $0.21 EPS, Q2 2019 earnings at $0.22 EPS, Q3 2019 earnings at $0.23 EPS, Q4 2019 earnings at $0.25 EPS and FY2019 earnings at $0.91 EPS.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on BRT Apartments (BRT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Biotech Stocks For 2021: Madison Square Garden Inc.(MSG)

The Madison Square Garden Company, together with its subsidiaries, operates in the sports, entertainment, and media businesses primarily in the United States. The company operates in three segments: MSG Media, MSG Entertainment, and MSG Sports. The MSG Media segment produces and develops content for various distribution platforms, including content originating from the company?s venues. It consists of the MSG Networks and the Fuse Networks, which offer sports and musical content. This segment also manages interactive businesses that comprise a range of targeted websites; and wireless, video on demand, and digital platforms. The MSG Entertainment segment creates, produces, and/or presents various live productions, as well as presents or hosts other live entertainment events, such as concerts, family shows, special events, and theatrical productions. The MSG Sports segment owns and operates sports franchises. This segment also owns other sports properties, including the pre sentation of a range of live sporting events, such as professional boxing, college basketball, track and field, and tennis. The company owns the Madison Square Garden complex in New York City, which includes an arena and a theater; and The Chicago Theatre in Chicago. It leases Radio City Music Hall and the Beacon Theatre in New York City. The company is based in New York, New York. As of February 09, 2010, Madison Square Garden, Inc. operates independently of Cablevision Systems Corporation.

Advisors’ Opinion:

  • [By Motley Fool Transcribers]

    The Madison Square Garden Co (NYSE:MSG)Q22019 Earnings Conference CallFeb. 01, 2019, 10:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Logan Wallace]

    PNC Financial Services Group Inc. trimmed its holdings in Madison Square Garden Co (NYSE:MSG) by 4.1% during the second quarter, HoldingsChannel reports. The firm owned 164,951 shares of the company’s stock after selling 7,114 shares during the period. PNC Financial Services Group Inc.’s holdings in Madison Square Garden were worth $51,166,000 at the end of the most recent reporting period.

  • [By Shane Hupp]

    Imperial Capital initiated coverage on shares of Madison Square Garden (NYSE:MSG) in a research note issued to investors on Tuesday, Marketbeat.com reports. The firm issued an outperform rating and a $372.00 price target on the stock.

Best Biotech Stocks For 2021: Ohr Pharmaceuticals, Inc.(OHRP)

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating OHR-102 eye drops, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, retinal vein occlusion, and proliferative diabetic retinopathy. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as steroid induced glaucoma, allergies, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on OHR Pharmaceutical (OHRP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    OHR Pharmaceutical Inc (NASDAQ:OHRP)’s share price fell 9.1% during trading on Tuesday . The stock traded as low as $0.22 and last traded at $0.24. 16,800 shares were traded during trading, a decline of 98% from the average session volume of 1,040,668 shares. The stock had previously closed at $0.22.

  • [By Shane Hupp]

    OHR Pharmaceutical Inc (NASDAQ:OHRP)’s share price hit a new 52-week high and low on Thursday . The company traded as low as $0.18 and last traded at $0.19, with a volume of 5632 shares traded. The stock had previously closed at $0.19.

  • [By Paul Ausick]

    Ohr Pharmaceuticals Inc. (NASDAQ: OHRP) dropped nearly 13% Tuesday to post a new 52-week low of $0.24. Shares closed at $0.27 on Friday and the stock’s 52-week high is $2.18. Volume was around 1 million, about a third of the daily average of about 3.3 million. The company had no specific news Tuesday.

Leave a Reply

Your email address will not be published. Required fields are marked *